Morgan Stanley’s Dynavax Technologies DVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,653,993
Closed -$25.4M 8342
2025
Q4
$25.4M Sell
1,653,993
-4,761
-0.3% -$52.4K ﹤0.01% 2710
2025
Q3
$16.5M Sell
1,658,754
-5,586
-0.3% -$58.1K ﹤0.01% 3065
2025
Q2
$16.5M Sell
1,664,340
-820,852
-33% -$8.65M ﹤0.01% 2992
2025
Q1
$32.2M Sell
2,485,192
-1,006,137
-29% -$13.3M ﹤0.01% 2212
2024
Q4
$44.6M Buy
3,491,329
+414,479
+13% +$5.01M ﹤0.01% 1934
2024
Q3
$34.3M Buy
3,076,850
+83,352
+3% +$919K ﹤0.01% 2228
2024
Q2
$33.6M Buy
2,993,498
+369,275
+14% +$4.3M ﹤0.01% 2132
2024
Q1
$32.6M Sell
2,624,223
-2,382,021
-48% -$31.1M ﹤0.01% 2172
2023
Q4
$70M Buy
5,006,244
+2,963,961
+145% +$41.2M ﹤0.01% 2089
2023
Q3
$30.2M Sell
2,042,283
-37,910
-2% -$533K ﹤0.01% 2046
2023
Q2
$26.9M Sell
2,080,193
-25,117
-1% -$286K ﹤0.01% 2154
2023
Q1
$20.7M Buy
2,105,310
+64,592
+3% +$689K ﹤0.01% 2381
2022
Q4
$21.7M Buy
2,040,718
+628,657
+45% +$7.3M ﹤0.01% 2257
2022
Q3
$14.7M Sell
1,412,061
-72,402
-5% -$943K ﹤0.01% 2541
2022
Q2
$18.7M Buy
1,484,463
+221,078
+17% +$2.35M ﹤0.01% 2368
2022
Q1
$13.7M Sell
1,263,385
-163,134
-11% -$1.98M ﹤0.01% 2531
2021
Q4
$20.1M Sell
1,426,519
-447,027
-24% -$7.36M ﹤0.01% 2135
2021
Q3
$36M Buy
1,873,546
+83,851
+5% +$1.11M ﹤0.01% 1532
2021
Q2
$17.6M Buy
1,789,695
+1,141,462
+176% +$10.4M ﹤0.01% 2293
2021
Q1
$6.37M Buy
648,233
+195,304
+43% +$1.61M ﹤0.01% 3149
2020
Q4
$2.02M Buy
452,929
+39,124
+9% +$177K ﹤0.01% 4155
2020
Q3
$1.79M Sell
413,805
-153,879
-27% -$1.1M ﹤0.01% 3754
2020
Q2
$5.03M Buy
567,684
+177,961
+46% +$899K ﹤0.01% 2659
2020
Q1
$1.38M Buy
389,723
+175,617
+82% +$814K ﹤0.01% 3689
2019
Q4
$1.23M Buy
214,106
+122,979
+135% +$658K ﹤0.01% 4393
2019
Q3
$326K Sell
91,127
-382,667
-81% -$1.48M ﹤0.01% 4883
2019
Q2
$1.89M Buy
473,794
+354,760
+298% +$2.06M ﹤0.01% 3817
2019
Q1
$870K Sell
119,034
-402,278
-77% -$3.93M ﹤0.01% 4208
2018
Q4
$4.77M Buy
521,312
+6,207
+1% +$68.7K ﹤0.01% 2963
2018
Q3
$6.39M Sell
515,105
-41,122
-7% -$556K ﹤0.01% 2921
2018
Q2
$8.48M Buy
556,227
+99,698
+22% +$1.72M ﹤0.01% 2550
2018
Q1
$9.06M Buy
456,529
+31,756
+7% +$548K ﹤0.01% 2437
2017
Q4
$7.94M Sell
424,773
-162,471
-28% -$3.26M ﹤0.01% 2630
2017
Q3
$12.6M Buy
587,244
+409,121
+230% +$6.47M ﹤0.01% 2045
2017
Q2
$1.72M Buy
178,123
+62,265
+54% +$404K ﹤0.01% 3936
2017
Q1
$688K Sell
115,858
-41,118
-26% -$198K ﹤0.01% 4644
2016
Q4
$620K Sell
156,976
-447,382
-74% -$3.28M ﹤0.01% 4794
2016
Q3
$6.34M Buy
604,358
+314,073
+108% +$4.51M ﹤0.01% 2443
2016
Q2
$4.23M Buy
290,285
+164,381
+131% +$2.81M ﹤0.01% 2765
2016
Q1
$2.42M Buy
125,904
+51,815
+70% +$1.05M ﹤0.01% 3191
2015
Q4
$1.79M Sell
74,089
-56,079
-43% -$1.4M ﹤0.01% 3591
2015
Q3
$3.19M Sell
130,168
-54,079
-29% -$1.53M ﹤0.01% 3064
2015
Q2
$4.32M Buy
184,247
+37,647
+26% +$820K ﹤0.01% 2922
2015
Q1
$3.29M Sell
146,600
-12,452
-8% -$239K ﹤0.01% 3139
2014
Q4
$2.68M Buy
159,052
+13,411
+9% +$204K ﹤0.01% 3297
2014
Q3
$2.08M Sell
145,641
-7,359
-5% -$106K ﹤0.01% 3396
2014
Q2
$2.45M Buy
153,000
+7,557
+5% +$114K ﹤0.01% 3318
2014
Q1
$2.63M Sell
145,443
-2,929
-2% -$54.3K ﹤0.01% 3188
2013
Q4
$2.91M Sell
148,372
-7,681
-5% -$112K ﹤0.01% 3084
2013
Q3
$1.86M Buy
156,053
+144,917
+1,301% +$1.82M ﹤0.01% 3291
2013
Q2
$123K Buy
+11,136
New +$235K ﹤0.01% 5023

Other funds holding DVAX

Morgan Stanley's DVAX Position: Q1 2026 in Review

Morgan Stanley sold out of Dynavax Technologies (DVAX) in Q1 2026, closing a stake of 1,653,993 shares — an estimated $25.4M sold.

Morgan Stanley first reported a position in DVAX in Q2 2013 and held it in 51 quarters. The position peaked at $70M in Q4 2023. 1 fund tracked by Wall St. Rank holds DVAX as of Q1 2026.

  • Morgan Stanley reported no remaining Dynavax Technologies position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 1,653,993 Dynavax Technologies shares in Q1 2026, an estimated $25.4M.
  • Morgan Stanley first reported a position in Dynavax Technologies in Q2 2013 and held it in 51 quarters.
  • Morgan Stanley's Dynavax Technologies position peaked at $70M in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Dynavax Technologies as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.